Kornimate/medical-research-clean huggingface dataset:
antithymocyte globulin and cyclosporine in treating low risk patients with myelodysplastic syndrome

Conditions: Myelodysplastic Syndrome

Summary: the different mechanisms of action between antithymocyte globulin and cyclosporine can improve the effectivity when both are used in combination in patients with myelodysplastic syndrome.

patients are treated with: antithymocyte globulin (timoglobulin sangstat) * 2,5 mg/kg/day iv over 8 hours on days 1-4 * total dose: 10 mg/kg * calculated dose adjusted to ideal weight * especial considerations: paracetamol 1 gr (oral or iv) dexclorfeniramine 5 mg iv methylprednisolone 1 mg/kg iv 30 minutes before timoglobulin and repeat if necessary at 4 hours - platelet transfusion if platelet count is \< 50 x 109/l cyclosporine (sandimmun neoral) -2,5 mg/kg/12 h over 3 months

Eligibility criteria:
inclusion criteria: * diagnosis of low or intermediate risk myelodysplastic syndrome (mds) (or high risk patient not eligible to intensive chemotherapy or for bone marrow transplantation), excluding chronic myelomonocytic leukemia * at less one of two following conditions: * transfusion dependence: 1)packed red blood cell transfusions greater than 2 times; 2)untransfused hemoglobin level no greater than 10 g/dl; 3)platelet transfusions greater than 1 time * infection grade iii or iv secondary to neutropenia * ecog \< or = 2 exclusion criteria: * chronic myelomonocytic leukemia * creatinine greater than 2 mg/dl * bilirubin greater than 2.5 mg/dl * history of heart failure * history of allergy to rabbit proteins

Keywords: myelodysplastic syndrome antithymocyte globulin cyclosporine
efficacy and safety of sofosbuvir plus ribavirin in japanese adults with chronic genotype 2 hcv infection

Conditions: Hepatitis C

Summary: this study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (sof) plus ribavirin (rbv) in japanese participants with chronic genotype 2 hepatitis c virus (hcv) infection.


Eligibility criteria:
inclusion criteria: * chronic genotype 2 hcv-infection * male or female, age ≥ 20 years * body weight ≥ 40 kg * hcv rna ≥ 10,000 iu/ml at screening exclusion criteria: * current or prior history of clinically significant illness other than hcv * pregnant or nursing female or male with pregnant female partner * chronic liver disease of a non-hcv etiology * infection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv)

Keywords: hcv genotype 2 (gt-2)
screening for obstructive sleep apnea in medical patients

Conditions: Obstructive Sleep Apnea

Summary: obstructive sleep apnea (osa) is highly prevalent in the general population and is associated with multiple adverse cardiovascular consequences. screening for osa is recommended in those with typical symptoms, such as daytime sleepiness, loud snoring, or abrupt awakenings with gasping or choking. patients admitted to the general medical wards with these symptoms will be evaluated for the possibility of having osa.

obstructive sleep apnea (osa) is a disease that is highly prevalent in all communities and is associated with adverse cardiovascular events. screening for osa is recommended in men and women who have the typical symptoms, including snoring, daytime sleepiness, or abrupt awakenings with choking or gasping. osa screening is also recommended for those with resistant hypertension, bradyarrhythmias, and atrial fibrillation. heart failure patients should also be screened for osa. it is very important to increase the use of osa screening especially in patients admitted to the medical floor in tertiary care hospitals. no study has evaluated this topic in the middle east in the past.

Eligibility criteria:
inclusion criteria: * willing to sign an informed consent * patient is admitted to the medical ward in a tertiary hospital exclusion criteria: * patients known to have obstructive sleep apnea. * patients younger than 18 years of age

Keywords: obstructive sleep apnea symptomatology middle east
a prospective observational registry of peripheral use of angiojet rheolytic thrombectomy with mid-length catheters

Conditions: Peripheral Vascular Diseases; Thrombosis; Venous Thrombosis

Summary: this registry collects observational data about how mid-length angiojet catheters (ie xpeedior and dvx models) are used in routine clinical practice.

the pearl registry collects real world data about mid-length angiojet catheters to: * characterize usage patterns, treatment approaches, and targeted vessels * document treatment strategies, including specific techniques and concomitant therapies * collect outcome data during initial hospitalization and at a 3-month follow-up phone call or visit * evaluate the frequency of specific clinical events in relation to risk factors, diagnosis, and treatments provided * identify treatment strategies that may optimize procedural and clinical outcomes, to facilitate development of treatment guidelines * offer sites a valuable resource for tracking usage and performance of the angiojet system at their institution information collected by the pearl registry is intended for educational and clinical research purposes only.

Eligibility criteria:
inclusion criteria: * patient has been treated with a mid-length angiojet catheter(defined as 90-120 cm in length) * patient has provided appropriate authorization per institutional policy and procedure. exclusion criteria: * none

Keywords: peripheral thrombosis dvt limb ischemia av access angiojet thrombectomy
serum immunological profiles in head and neck cancer patients receiving curative radiotherapy

Conditions: Head and Neck Cancers Patients

Summary: the purpose of the study is to investigate the clinical usefulness of serum levels of immunologic profiles including pro/anti-inflammatory interleukins, other detectable serum biomarkers including transforming growth factor b1 (tgfb1) or soluble major histocompatibility complex class i chain-related peptide a (smica), and leukocyte subpopulations in head and neck cancers patients receiving curative radiotherapy, as prognostic biomarkers for disease recurrence and survival.


Eligibility criteria:
inclusion criteria: * patients with head and neck cancer receiving curative radiotherapy in ntuh radiation therapy department. exclusion criteria: * patients with head and neck cancer not receiving curative radiotherapy in ntuh radiation therapy department.
investigation of the relationship between plantar foot pressure and balance in morbidly obese individuals

Conditions: Obesity, Morbid; Foot Deformities

Summary: the fact that changes in plantar pressure during walking and in a fixed position in morbidly obese individuals and the relationship between postural oscillations and balance have not been fully elucidated creates a need in this area. in this study, primary aim is to investigate the change in plantar foot pressure, balance parameters and the relationship between them in morbidly obese individuals compared to healthy individuals.


Eligibility criteria:
inclusion criteria: * individuals between the ages of 18-60 * bmi ≥ 40 kg/m2, morbidly obese individual * no surgical operation in the last 6 months * non-obese healthy adult individuals will be included in the study as the control group. exclusion criteria: * having a musculoskeletal disorder or systemic disease that will interfere with physical activity * presence of balance problems that will prevent physical activity * presence of psychiatric or neurological disease affecting cooperation and cognitive functions * presence of acute pain * presence of uncontrolled diabetes and hypertension * having any communication problems

Keywords: plantar pressure dynamic balance morbid obesiy gait
respiratory syncytial virus (rsv) burden in older adults in primary care in the netherlands

Conditions: RSV Infection

Summary: rsv infection is a leading cause of medical care in older adults, sometimes leading to hospital admission and severe outcomes. although the majority of rsv infections are managed outside hospitals, little is known on the burden of rsv in older adults in the primary care setting. accurate estimates of the rsv burden in primary care is particularly relevant since vaccines against rsv infection in older adults will likely become available for the general population soon. the use of high-quality point-of-care (poc) molecular viral diagnostics allows to identify rsv infected older adults and would therefore contribute to fill one of the most important gaps in knowledge facilitating implementation of rsv vaccination of older adults with this prospective, observational study, we aim to define the disease burden of rsv infection in older adults in the primary care setting.

th rapid study is a prospective, observational study in dutch primary care practices during two rsv seasons. as part of routine care, rapid molecular viral diagnostic testing on respiratory samples will be offered to all older adults attending the primary care physician because of symptoms of acute respiratory tract infection (arti). rsv positive cases will be included for further study. participants will be asked to fill out three questionnaires by phone or by online at day 0, 14 and 30 after the gp-visit. the main endpoint is the burden of medically attended rsv infection in the dutch primary care setting, quantified using several clinical and socioeconomic parameters, including (but not limited to) clinical symptoms and their duration, medicine use, hospitalisation rate, quality of life and ability to perform normal daily activities. secondary, data on health care consumption and indirect costs will be collected and we will assess the effect of age and severe comorbidity on clinical course of rsv disease. a population size of 1000 older adults age \>60 years presenting with acute respiratory symptoms to the general practitioner (gp) during rsv season will be tested for rsv as part of routine care. we expect about 100 rsv+. based on our sample size calculation, 100 rsv+ cases would provide sufficient accuracy for estimating the relevant outcomes.

Eligibility criteria:
inclusion criteria: * age (≥60 years of age) * rsv positive * subject is willing and able to give informed consent for participation in the study * subject is willing and able to adhere to protocol-specific procedures exclusion criteria: * subject is not able to understand and communicate in the local language or english. * previous or current participation in rsv interventional trial (vaccine, antivirals)

Keywords: older adults rsv burden outpatient primary care
precision biomarker-guided management of tuberculosis contacts: a discrete choice experiment

Conditions: Tuberculosis (TB)

Summary: this study is part of a broader programme of work to develop and pilot a randomised-controlled trial of new tests to identify people who will benefit most from preventive treatment for tuberculosis (tb). the aim of the current study is to explore factors affecting patient decisions to start preventive treatment. the specific objectives are to understand how patients make decisions about preventive treatment initiation for tb (stage 1); and to design and conduct a "discrete choice experiment" survey to further evaluate preferences (stage 2).

we will perform up to 30 semi-structured interviews among people undergoing testing for latent tb infection, as part of routine clinical screening programmes (stage 1). adults (aged ≥18 years) who have been or are being tested for ltbi in routine clinical services will be eligible for inclusion through purposive sampling. the findings from the qualitative study will then be used to inform the a discrete choice experiment (dce). the dce will be conducted to quantify the trade-off between future tb risk and preventive treatment acceptance, from patient and healthcare provided perspectives (stage 2).

Eligibility criteria:
inclusion criteria: * adults (aged ≥18 years) who have been tested for latent tb infection in routine clinical services, or are eligible for testing. eligible people for testing include migrants from countries with high tb incidence (entered uk within 5 years), people with recent contact with a person with tb disease, and people eligible for ltbi screening prior to starting immunosuppression or through occupational health testing. exclusion criteria: * unable to provide informed consent.

Keywords: preference discrete choice experiment qualitative latent tuberculosis infection
impact of cilostazol versus cilostazol and selenium combination on the healing of diabetic foot ulcer patients

Conditions: Wound Heal

Summary: the growing incidence of dm can lead to the increased prevalence of diabetic foot complications, which have become a serious medical, social, and economic concern of global importance. this study aims to find a novel intervention that improve wound healing in diabetic foot ulcer to improve patients' quality of life, reduce amputation rate, and reduce the mortality rate among diabetic foot ulcer patients


Eligibility criteria:
inclusion criteria: * eligible patients will be adult diabetic patients aged 18 years and older with non-ischemic diabetic foot ulcers wagner's grade 2, 3, and 4. exclusion criteria: 1. wagner's grade 5 patients (because of the indications for amputation). 2. patients with poor glycemic control at the time of inclusion (hba1c\>12%). 3. patients who need either direct graft or indirect revascularization procedure during the study. 4. patients with cilostazol or selenium allergy. 5. patients with cilostazol contraindications (heart failure, bleeding disorder). 6. patients with a history of comorbidities that interfere with wound healing (cancers, congestive heart failure, end-stage renal disease, and liver failure). 7. presence of clinical signs of active infection unresponsive to oral antibiotics (oedema, erythema, discharge, regional lymph node enlargement, pain, or fever). 8. patients who take medications that interfere with wound healing (glucocorticoids, immunosuppressive and cytotoxic drugs) at the time of inclusion. 9. non-diabetic patients with foot wounds due to vascular or dermatological reasons.
a study of ibandronate (boniva) to evaluate satisfaction in women with post-menopausal osteoporosis or osteopenia

Conditions: Postmenopausal Osteoporosis

Summary: this study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate. the anticipated time on study treatment is 6 months, and the target sample size is 1776 individuals.


Eligibility criteria:
inclusion criteria: - women who had been receiving once-weekly alendronate or risedronate for treatment or prevention of post-menopausal osteoporosis for greater than or equal to (\>=) 3 months exclusion criteria: * inability to stand or sit upright for \>=60 minutes * hypersensitivity to bisphosphonates * inability to swallow a tablet whole * malignant disease diagnosed within previous 10 years (except resected basal cell cancer).
l-dep/dep regimen and pd-1 antibody as a treatment for relapse/refractory ebv-hlh

Conditions: Hemophagocytic Lymphohistiocytosis

Summary: this study aimed to investigate the efficacy and safety of l-dep (l-asparaginasum, liposomal doxorubicin, etoposide and methylprednisolone) together with pd-1 antibody as an treatment for relapse/refractory ebv associated hemophagocytic lymphohistiocytosis.

pd-1 antibody added to the dep regimen （with or without asparaginases） in ebv-hlh

Eligibility criteria:
inclusion criteria: 1. meet hemophagocytic lymphohistiocytosis (hlh)-04 diagnostic criteria;patients were diagnosed with ebv associated hlh (ebv-hlh). 2. ebv-dna in peripheral blood or eber in tissue were positive. 3. treated with hlh-94 no less than 2 weeks before enrollment and did not achieve at least partial response 4. the patient is expected to be unable to undergo allogeneic hematopoietic stem cell transplantation in the short term due to various reasons (physical status, economic reasons, donor reasons, etc.) 5. the expected survival time is more than 1 month. 6. age ≤ years old, gender is not limited. 7. serum creatinine ≤ 1.5 times normal；after infusion, fibrinogen can be corrected to ≥0.6g/l. 8. serum human immunodeficiency virus(hiv) antigen or antibody negative； hepatitis c virus (hcv) antibody is negative, or hcv antibody is positive, but hcv rna is negative；hbv copies less than 1e+03 copies/ml. 9. the left ventricular ejection fraction (lvef) was normal. 10. no uncontrollable infection. 11. contraception for both male or female. 12. informed consent obtained. exclusion criteria: 1. allergic to doxorubicin and/or etoposide and/or pd-1 antibody injection 2. severe myocardial injury, myocardial enzymes ck, ck-mb increased more than 3 times uln (upper limit of normal) 3. heart function above grade ii (nyha). 4. thyroid dysfunction 5. serious mental illness; 6. active hemorrhage of internal organs 7. previously received l-dep regimen for hlh-targeted treatment, but the treatment was ineffective or relapsed 8. accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2 9. participate in other clinical research at the same time.

Keywords: hemophagocytic lymphohistiocytosis dep l-asparaginasum pd-1 antibody
guided growth of the proximal femur to prevent further hip migration in cerebral palsy patients

Conditions: Cerebral Palsy; Hip Dislocation

Summary: in recent literature, the potential of guided growth of the proximal femur to modify hip growth in patients with cerebral palsy has been shown. using medial hemi-epiphysiodesis of the proximal femur (tmh-pf) morphology of hips at risk of symptomatic (sub)luxation in cerebral palsy (cp) can be changed, aiming to reduce further hip migration and the need for more invasive surgical treatment modalities. further research is necessary to assess if the results of tmh-pf in combination with adductor tenotomies are significantly better than the results of the current standard of care; adductor tenotomies alone. the investigators objective is to determine whether guided growth of the proximal femur decreases the risk of further hip migration and need for further surgery in cerebral palsy patients.


Eligibility criteria:
inclusion criteria: * spastic cp * gmfcs level iv-v * aged 2-8 years * at least one hip with an abduction in flexion ≤ 40 degrees * migration percentage of 30-50% * head shaft angle \> 145 exclusion criteria: * not fit for surgery * history of bony hip surgery to the affected hip * severe acetabular dysplasia defined as a gothic arch, an incongruent joint or an acetabular index \> 30 degrees, consistent with a2 and a3 acetabular deformity according to robin and graham in an adequately performed radiographs
better sleep in psychiatric care - adhd.

Conditions: Sleep Problem; ADHD

Summary: cognitive behavioral therapy (cbt) is treatment of choice for insomnia (cbt-i). many patients in psychiatric care have sleep problems including insomnia, but are rarely given the choice to participate in cbt to improve their sleep. patients with adhd is a patient group with high levels of sleep difficulties. sleep problems in this patient group can be both more general such as insomnia, but can also be related to the adhd itself and to the use of adhd medication. in a previous pilot study, the investigators developed a version of cbt-i that would target sleep problems in this population. the basis was cbt-i, but with more emphasis on sleep promoting behaviors specific to adhd (e.g. appropriate timing of adhd-medication), techniques that would also alleviate sleep phase problems, (e.g. the systematic use of light and darkness), and techniques to target more general sleep disturbing habits (e.g. not winding down before bed time), that are also common in patients with adhd. this treatment was well tolerated and gave moderate effects on insomnia severity in the pilot study. in a naturalistic randomized controlled trial, the investigators now evaluate the effects of this psychological treatment on sleep and symptoms of adhd in patients at the adhd-clinics, northern stockholm psychiatry, sweden.


Eligibility criteria:
inclusion criteria: * being a patient at the adhd-clinics northern stockholm psychiatry * experiencing sleep problems (subjective report) exclusion criteria: * none

Keywords: cognitive behaviour therapy psychological intervention
superior and inferior capsulotomy in bipolar hemiarthroplasty using posterior approach

Conditions: Femoral Neck Fractures

Summary: investigators will compared the clinical outcomes between superior capulotomy and inferior capsulotomy in bipolar hemiarthropalsty using posterior approach.

primary clinical outcome will be dislocation within 1 year after surgery.

Eligibility criteria:
inclusion criteria: * more than 50 years old * displaced femoral neck fractgure exclusion criteria: * less than 50 years old

Keywords: femoral neck fractures
ultralong-segment barrett's esophagus: towards a capsule-sponge surveillance strategy

Conditions: Barrett Esophagus

Summary: the purpose of this study is to evaluate the endosign capsule sponge test as a novel surveillance method in patients with an ultralong-segment barrett's esophagus.

in this study we will investigate the concordance between the endosign capsule sponge test and esophagogastroduodenoscopy (egd) by an expert endoscopist to detect dysplasia and/or esophageal adenocarcinoma (eac) in patients with an ultralong-segment barrett's esophagus. patients will receive both the endosign test and an egd, after which we will compare both outcomes. to detect dysplasia and/or eac on the cells collected by the endosign test, we will look at cellular atypia and use p53 immunohistochemistry and novel biomarkers. in the future the endosign test could perhaps replace egd in the surveillance of barrett's esophagus patients.

Eligibility criteria:
inclusion criteria: * any participant 18 years and above, with ultralong-segment barrett's esophagus and clinically fit for an endoscopy * ability to provide informed consent exclusion criteria: * individuals with a diagnosis of an oro-pharynx, esophageal or gastro-esophageal tumor (t2 staging and above), or symptoms of dysphagia * esophageal varices or stricture requiring dilatation of the esophagus * individuals who have had a cerebrovascular event \< 6 months prior where their swallowing has been affected * patients who have had previous treatments such as photodynamic therapy (pdt), radiofrequency ablation (rfa) or argon plasma coagulation (apc) for dysplastic barrett's esophagus * participants who are unable to provide informed consent * participants under age 18 years